REDX

Hardman & Co

Redx Pharma Phase I trial resumed

REDX is a clinical-stage R&D company focused on drugs targeting oncology and fibrotic disease. 2018 was a year that reset the benchmarks – new management team, restructured organisation focused on

Hardman & Co

Redx Pharma Streamlined, focused and good value

Redx Pharma (LON:REDX) is a clinical-stage R&D company focused on drugs targeting oncology and fibrotic disease. 2018 was a year that reset the benchmarks – new management team, restructured organisation

Hardman & Co

Redx Pharma Back to the clinic

Redx Pharma Plc (LON:REDX) new management team is continuing to focus its financial resources on progressing its lead candidates in oncology and fibrotic disease into the clinic. When the first

Hardman & Co

Redx Pharma Clinical and corporate update

The new management team of Redx Pharma Plc (LON:REDX) is focusing its financial resources (ca.£10m) on progressing its lead candidates in oncology and fibrotic disease into the clinic. Although the

Hardman & Co

Redx Pharma Streamlined and clean

Redx Pharma Plc (LON:REDX) has emerged from administration with a refocused R&D pipeline and in a very clean financial state with £13.6m net cash in the bank. The group’s strategy